Table S1

(A)

	$C_{imatinib}$ [µM] Ba/F3-BCR-ABL	$C_{imatinib}$ [µM] K562	$C_{dasatinib}$ [µM] K562
Lysate (diluted)	**0.52 (±0.09)**	**0.81 (±0.23)**	**0.000583 (±0.00004)**
Intracellular concentration (calculated)	**10994**	**6513**	**4.688**

(B)

	Diameter [µM]	Calculated volume/cell [L]
Ba/F3-BCR-ABL	**12.18 (±1.63)**	**0.946×10^{-12}**
K562	**16.81 (±1.93)**	**2.487×10^{-12}**

Table S1: TKI concentrations measured by HPLC / LC-MS/MS in cellular lysates

(A) TKI concentrations ±SEM measured by HPLC / LC-MS/MS in cellular lysates treated with 25µM imatinib or 100nM dasatinib for 2h as indicated followed by drug wash-out. Intracellular TKI concentrations were calculated based on the mean cellular volume.
(B) Mean size in µm ±SD of Ba/F3-BCR-ABL cells and K562 cells. In total, 100 cells of each cell line were measured. Intracellular imatinib concentration was calculated based on the assumption that cells are spherical ($V = 4/3 \times \pi \times r^3$). Thus, the total cellular volume for 0.2×10^6 cells is 0.19µl for Ba/F3-BCR-ABL cells and 0.5µl for K562 cells.